AI-generated summary
The authors systematically reviewed randomized clinical trials and controlled animal studies of transcranial photobiomodulation for traumatic brain injury, stroke, Parkinson's and Alzheimer's disease. They report that human trials gave non-homogeneous results, that no trials were found for Alzheimer's or Parkinson's, and that no adverse events were reported. Larger confirmatory trials are needed.
- Who or what was studied
- Patients with traumatic brain injury, stroke, Parkinson's disease or Alzheimer's disease in human randomized trials, plus controlled animal studies
- Limits stated in the abstract
- The authors state that human trial outcomes were not homogeneous, no trials covered Alzheimer's or Parkinson's disease, and the evidence base is too limited for a definite therapeutic decision.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Tinnitus, Traumatic brain injury, Brain injury, Stroke, Low-level laser therapy, Light-emitting diode. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.